Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma.
CONCLUSION: We report novel methylation sites that could be used as powerful tools for predicting risk factors for poorer survival in patients with LUSC.
PMID: 32924987 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Docetaxel | Genetics | Men | Skin Cancer | Squamous Cell Carcinoma | Study | Taxotere | Training | Universities & Medical Training